4-氨基-3-硝基苯乙酸 | 116435-82-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基-3-硝基苯乙酸
• 英文名称: 4-amino-3-nitrophenylacetic acid
• 英文别名: 2-(4-Amino-3-nitrophenyl)acetic acid
• CAS: 116435-82-6
• 化学式: C₈H₈N₂O₄
• mdl: MFCD09842459
• 分子量: 196.163
• InChiKey: GOYNTGDWVOXIIX-UHFFFAOYSA-N

物化性质

• 熔点：
  144-145 °C
• 沸点：
  449.3±30.0 °C(Predicted)
• 密度：
  1.497±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  4-氨基-3-硝基苯乙酸 在 palladium catalyst 盐酸 、 硼烷四氢呋喃络合物 、 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 24.0h， 生成 N-[2-(Benzimidazol-5-yl)ethyl]-N-[(r)-(+)-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-ylmethyl]-N-methylamine
  参考文献：
  名称：

  Structure−Activity Studies for a Novel Series of N-(Arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamines Possessing Dual 5-HT Uptake Inhibiting and α₂-Antagonistic Activities

  摘要：

  In search of an alpha(2)-antagonist/5-HT uptake inhibitor as a potential new class of antidepressant with a more rapid onset of action, compound 3 was prepared and observed to possess high affinity for the alpha(2)-receptor (K-i = 6.71 nM) and the 5-HT uptake site (20.6 nM). A series of tertiary amine analogs of 3 were synthesized and assayed for their affinity at both the alpha(2)-receptor and the 5-HT uptake site. The structure-activity relationship reveals that a variety of structural modifications to the arylethyl fragment are possible with retention of this dual activity. On the tetralin portion, 5-OMe substitution and the (R) stereochemistry at C-l are optimal with alternate substitutions producing compounds retaining high affinity for the alpha(2)-receptor but lacking affinity for the 5-HT uptake site. Data for several rigidified 5-O-alkyl analogs suggests that the favored orientation of the oxygen lone pairs may be away from the g-position of the tetralin.

  DOI：

  10.1021/jm960723m
• 作为产物：
  描述：

  对氨基苯乙腈 在 盐酸 、 硝酸 作用下， 生成 4-氨基-3-硝基苯乙酸
  参考文献：
  名称：

  Gabriel, Chemische Berichte, 1882, vol. 15, p. 838

  摘要：

  DOI：

文献信息

• [EN] HETEROCYCLIC KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE HETEROCYCLIQUE
  申请人：ABBOTT LAB

  公开号：WO2004076424A1

  公开（公告）日：2004-09-10

  Compounds having the formula (I) are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有公式(I)的化合物对于抑制蛋白激酶是有用的。还公开了制造这些化合物的方法、包含这些化合物的组合物以及使用这些化合物的治疗方法。
• Tetrahydropyridly-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same
  申请人：——

  公开号：US20040138264A1

  公开（公告）日：2004-07-15

  The present invention relates to compounds of formula (I): 1 in which X represents N or CH; R 1 represents a hydrogen or halogen atom or a CF 3 group; R 2 and R 3 independently represent a hydrogen atom or a methyl group; n is 0 or 1; A represents an optionally substituted nitrogenous heterocycle; and to their N-oxides and to their salts or solvates, to the pharmaceutical compositions and the medicaments comprising them, and to a process for their preparation.

  本发明涉及式(I)的化合物： 其中X代表N或CH；R1代表氢原子或卤素原子或CF3基团；R2和R3分别代表氢原子或甲基基团；n为0或1；A代表一个可选择替代的含氮杂环；以及它们的N-氧化物、盐或溶剂化合物，包括含有它们的药物组合物和药物，以及它们的制备方法。
• [EN] HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DU FACTEUR DE CROISSANCE DES FIBROBLASTES
  申请人：GUANGDONG NEWOPP BIOPHARMACEUTICALS CO LTD

  公开号：WO2020119606A1

  公开（公告）日：2020-06-18

  Disclosed are heterocyclic compounds as inhibitors of FGFR-4 represented by formula (I). Also disclosed is a pharmaceutical composition that includes an inhibitor of FGFR-4. The compounds maybe used to treat diseases mediated with abnormality of FGFR-4 and /or FGF19, such as hepatocellular carcinoma and other forms of cancer.

  本发明涉及一种以式(I)表示的FGFR-4抑制剂的杂环化合物。还公开了一种包含FGFR-4抑制剂的药物组合物。这些化合物可用于治疗由FGFR-4和/或FGF19异常介导的疾病，如肝细胞癌和其他形式的癌症。
• Heterocyclic kinase inhibitors
  申请人：——

  公开号：US20040254159A1

  公开（公告）日：2004-12-16

  Compounds having the formula 1 are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有1式的化合物对于抑制蛋白激酶非常有用。还揭示了制备该化合物的方法，含有该化合物的组合物，以及使用该化合物进行治疗的方法。
• Substituted 1-sulfonylbenzimidazoles
  申请人：Eli Lilly and Company

  公开号：US04018790A1

  公开（公告）日：1977-04-19

  Certain 1-sulfonyl-2,5(6)-substituted-benzimidazole compounds are useful as antiviral agents.

  某些1-磺酰基-2,5（6）-取代苯并咪唑化合物可用作抗病毒剂。